A Unique AIDS Vaccine Candidate For Multiple HIV Strains

针对多种 HIV 病毒株的独特艾滋病候选疫苗

• 批准号: 6485866
• 负责人: Yu Geng
• 金额: $ 28.64万
• 依托单位: PROSCI, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-06-01 至 2004-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6485866
• 关键词: AIDS vaccines; HIV envelope protein gp120; active immunization; drug screening /evaluation; genetic strain; human immunodeficiency virus; immunomodulators; laboratory rabbit; ligands; molecular cloning; neutralizing antibody; peptide chemical synthesis; protein purification; recombinant proteins; vaccine development

DESCRIPTION: (Provided by Applicant) Development of a safe and effective AIDS vaccine has tremendous commercial potential and social impact and is a national priority. In response to the obstacles presented in AIDS vaccine development, a set of new concepts and designs is integrated to develop a new AIDS vaccine-adjuvant system. It includes a special design of immunogen HMP-gpl20, two novel adjuvants targeting B lymphocytes, and a new formulation of vaccine antigen-adjuvant. It could lead to a long-sought AIDS vaccine that elicits effective and long lasting neutralizing antibody responses to multiple HIV strains to prevent HIV infection and transmission. In the proposed Phase I study we will develop a new AIDS vaccine-adjuvant system, immunize animals, and detect general and neutralizing antibody activities that block HIV gpl20 binding to DC-SIGN. The investigators' experience, the preliminary data, the animal facility, and the company expertise make the scientific team competent to complete the objectives in this proposal. We anticipate that this novel AIDS vaccine-adjuvant system will induce strong neutralizing antibody activity and provide a model for elusive vaccines and a novel mechanism to enhance humoral immunity. The constructed HMP-gpl20, new adjuvants, and other reagents will be the basis for Phase II study. The neutralizing antibody activity will provide necessary information for phase II research and development.

描述：（由申请人提供）开发安全有效的辅助工具 疫苗具有巨大的商业潜力和社会影响，是国家 优先事项。为了应对艾滋病疫苗开发中提出的障碍， 一组新的概念和设计已整合以开发新的辅助工具 疫苗 - 辅助系统。它包括免疫原HMP-GPL20的特殊设计， 两个靶向B淋巴细胞的新型佐剂和一种新的疫苗配方 抗原辅助。它可能导致引起的长期艾滋病疫苗 对多发性艾滋病毒的有效且持久的中和抗体反应 菌株可防止HIV感染和传播。在提议的第一阶段 研究我们将开发一种新的艾滋病疫苗 - 辅助系统，免疫动物，并 检测一般和中和抗体活性，以阻止HIV GPL20 与DC-Sign结合。调查人员的经验，初步数据， 动物设施和公司专业知识使科学团队有能力 完成本提案中的目标。我们预计这部小说有助于 疫苗 - 辅助系统将引起强烈的中和抗体活性和 提供难以捉摸的疫苗的模型和一种新型机制来增强体液 免疫。构造的HMP-GPL20，新佐剂和其他试剂将是 II期研究的基础。中和抗体活性将提供 II期研究和开发的必要信息。